Actively Recruiting
Safety and Pharmacokinetics Study of IV TESP-0401 in Healthy Adults with Single and Multiple Doses
Led by Tes Pharma S.r.l. · Updated on 2026-09-14
68
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and how the body processes TESP-0401 in healthy adult volunteers. This randomized, placebo-controlled study aims to understand these factors after both single and multiple intravenous doses of the drug. The study is designed as a Phase 1 trial to carefully assess how TESP-0401 behaves in the body and to monitor any adverse effects in healthy participants. Participants will receive TESP-0401 or a placebo through intravenous infusion over 60 minutes while fasting. The study includes two parts Part A with single ascending doses and Part B with multiple ascending doses administered once daily for seven days. Each participant will be assigned randomly to either the experimental or placebo group in a parallel design. During the study, participants will be closely monitored for safety through clinical lab tests, vital signs, ECG readings, and physical exams up to eight days after the last dose. Researchers will measure drug concentrations, how quickly it reaches peak levels, clearance rates, half-life, volume of distribution, and drug accumulation over up to nine days. The entire participation includes confinement at the clinical research unit and adherence to study restrictions to ensure accurate monitoring of safety and pharmacokinetics.
CONDITIONS
Brief Title
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TESP-0401 in Healthy Participants
Research Team
J
Jennifer Martin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here